Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traumatic brain injury among hispanic children in the United States: a comprehensive systematic review of the literature.

Neurosurgical review·2026
Same author

Ancestral genetic homogeneity in preclinical models may shape outcome differences in pediatric brain cancer.

Cancer research·2026
Same author

A review of applications of automated ventricular parcellation from magnetic resonance imaging of the brain.

Frontiers in neurology·2026
Same author

Identifying Faculty Development Needs of Basic Science and Clinical Faculty in Preparation for Curriculum Change.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

Correction: Analytical validation of a metagenomic next-generation diagnostic platform for urinary tract infection in a Thai tertiary hospital setting: a BI-Biotia UTI cohort study.

Frontiers in cellular and infection microbiology·2026
Same author

Diverse high-fat diets drive multi-omic reprogramming that persists after dietary reversal.

bioRxiv : the preprint server for biology·2026
Same journal

Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation.

Neuro-oncology advances·2026
Same journal

Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives.

Neuro-oncology advances·2026
Same journal

Defining rapid early progression in glioblastoma-A volumetric approach.

Neuro-oncology advances·2026
Same journal

Medulloblastoma immune microenvironment resembles early brain development and reveals novel basophil- B cell- associated signatures.

Neuro-oncology advances·2026
Same journal

Prognostic impact of circulating vitamin D and genetic variants in the vitamin D pathway in glioblastoma.

Neuro-oncology advances·2026
Same journal

Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy?

Neuro-oncology advances·2026
See all related articles

Related Experiment Video

Updated: Dec 15, 2025

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

680

Missing diversity in brain tumor trials.

Birra Taha1, Graham Winston2, Umberto Tosi2

  • 1Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.

Neuro-Oncology Advances
|July 10, 2020
PubMed
Summary
This summary is machine-generated.

Minorities are underrepresented in brain tumor clinical trials, with data gaps persisting even in diverse cities. Most trials lack published race and ethnicity data, hindering equitable research for brain tumor treatments.

Keywords:
representationNew York Cityclinical trialsdiversityneuro-oncology

More Related Videos

Author Spotlight: Increasing TMS Accessibility Through Braiding Techniques for Diverse Hair Types
04:37

Author Spotlight: Increasing TMS Accessibility Through Braiding Techniques for Diverse Hair Types

Published on: August 9, 2024

1.2K
Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection
08:23

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Published on: May 9, 2022

4.8K

Related Experiment Videos

Last Updated: Dec 15, 2025

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

680
Author Spotlight: Increasing TMS Accessibility Through Braiding Techniques for Diverse Hair Types
04:37

Author Spotlight: Increasing TMS Accessibility Through Braiding Techniques for Diverse Hair Types

Published on: August 9, 2024

1.2K
Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection
08:23

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Published on: May 9, 2022

4.8K

Area of Science:

  • Neuro-oncology
  • Clinical trial research
  • Health equity

Background:

  • Brain tumors pose significant morbidity, necessitating robust clinical trials for effective treatment strategies.
  • Understanding ethnic and racial representation in these trials is crucial for identifying and addressing recruitment disparities.
  • Existing gaps in trial participation persist, even in highly diverse urban centers like New York City.

Purpose of the Study:

  • To quantify and map ethnic and racial representation in brain tumor clinical trials.
  • To identify potential gaps in trial recruitment and participation across different demographic groups.
  • To examine the availability of race and ethnicity data in published trial results.

Main Methods:

  • Analysis of brain tumor clinical trials registered on ClinicalTrials.gov (July 2005 - November 2017).
  • Utilized PubMed/MEDLINE and Google Scholar to retrieve trial publications and patient demographic data, including race or ancestry.
  • Compared participant demographics against general population data to assess representation.

Main Results:

  • 27% of analyzed trials had no published results; only 28.4% reported participant race/ethnicity.
  • Whites were overrepresented in metastatic and high-grade brain tumor trials (P < .001).
  • Blacks/African Americans, Hispanics, and Asians were underrepresented in high-grade trials (P < .001); Blacks/African Americans were also underrepresented in metastatic trials (P < .001).
  • Pediatric trials showed no representation gaps; similar disparities were observed in New York City.

Conclusions:

  • Minorities remain significantly underrepresented in brain tumor clinical trials despite increasing population diversity.
  • A substantial majority (70%) of brain tumor trials lack published race-based demographic information, despite ethical and legal mandates.
  • Addressing these representation gaps and improving data transparency are critical for advancing equitable brain tumor research and treatment.